Infrared Sciences trolls for buyer
Other headlines:iCAD installs MR image analysis softwareZiosoft shows new capabilities in Japan
iCAD installs MR image analysis software
A computer-aided detection system that identifies early signs of prostate cancer has begun operating at Research Medical Center in Kansas City, MO. VividLook by iCAD helps differentiate benign from malignant tumors, while locating and sizing tumors. The Kansas City site is the first installation of the product since iCAD last year purchased the developer of the software, CAD Sciences.
Ziosoft shows new capabilities in Japan
Visualization specialist Ziosoft unveiled new tools for its thin-client Ziostation system at the International Technical Exhibition of Medical Imaging April 17 to 19 in Yokohama, Japan. Among them were a SPECT/CT fusion application, MR cardiac function analysis, and 4D brain perfusion showing dynamic analyses using data from Toshiba's 320-slice CT scanner, none of which is yet available for sale in the U.S. Also featured at the Japanese conference was a load-balancing concept for clustering servers, as well as the new zioTerm free 2D and pay-per-study 3D application model aimed at academic users. Accessibility to medical images was further exemplified by proof-of-concept iPhone applications.
Infrared Sciences trolls for buyer
The maker of an infrared detector of breast cancer wants out. Infrared Sciences, manufacturer of the Sentinel BreastScan, is looking for a "strategic acquirer" interested in buying either the company or its assets. Infrared Sciences began putting out feelers last week after announcing the publication of a clinical study of the Sentinel BreastScan at Weill Medical College of Cornell University in the American Journal of Surgery. Company president and CEO Thomas DiCicco cited the current economic climate and lack of investment capital as keeping Infrared Sciences from securing the necessary investment funds to sustain the operation and grow the company.
"This will result in the company being forced to cease operation in the next few months," he said.
He urged "interested parties to contact the company as soon as possible."
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
